We will call the 55th meeting of the Standing Committee on Industry, Science and Technology to order. We have our third meeting today, pursuant to Standing Order 108(2), on our continuing study of Canada's access-to-medicines regime.
First of all, I want to apologize for the warm weather. I'm not exactly sure what happened, but I want to thank Mr. McTeague for bringing in the fresh air, as he usually does for this committee. He's one step closer to being competition commissioner of Canada.
We have our final meeting here. We have with us five representatives of either industry associations or companies.
First of all, from the Canadian Generic Pharmaceutical Association, we have Mr. Jim Keon, the president. Secondly, we have Mr. Jack Kay, the vice-chair, who is president and CEO of Apotex Incorporated. From Gilead Sciences Inc., we have Mr. Gregg Alton, senior vice-president and general counsel. From Canada's Research-Based Pharmaceutical Companies, first of all, we have the president, Mr. Russell Williams; secondly, we have Mr. Terry McCool, vice-president, corporate affairs, Eli Lilly Canada Inc.
Gentlemen, we have given ten minutes for each association. The Generic Pharmaceutical Association will have ten minutes, Gilead will have ten minutes, and Rx & D will have ten minutes.
We will start with Mr. Keon for a ten-minute opening statement.